The study failed to show a statistically significant reduction in depressive symptoms as measured by the Montgomery-Asberg Depression Rating Scale compared to a placebo, according to a Jan. 2 news release from the company.
The key secondary endpoint, a reduction in anhedonia measured by the Snaith-Hamilton Pleasure Scale, also did not achieve statistical significance. However, navacaprant showed an efficiency signal in female participants with a trend toward improvement in both depressive symptoms and anhedonia though the data were not conclusive.
The drug was generally well-tolerated, with a safety profile comparable to placebo. No adverse events were reported and there were no signals of increased suicidal ideation or behavior.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
